CUPERTINO, Calif. — December 29, 2025 — Leads & Copy — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”) announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva, will present at the Sachs 9th Annual Neuroscience Innovation Forum on January 11, 2026, in San Francisco, CA.
The presentation is scheduled for Sunday, January 11, 2026, at 1:20 PM PT at the Marines’ Memorial Club in San Francisco, CA. The presentation format will be a corporate presentation and will be given by Laxminarayan Bhat, Ph.D., of Reviva Pharmaceuticals.
Reviva is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. The company’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases.
Reviva’s pipeline includes two drug candidates, brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Laxminarayan Bhat, PhD, is the contact person for Reviva Pharmaceuticals Holdings, Inc.
PJ Kelleher of LifeSci Advisors, LLC, can be reached at pkelleher@lifesciadvisors.com for investor relations inquiries.
Source: Reviva Pharmaceuticals
